Clinical Trial: Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT07570810) titled 'Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM' on March 15.

Brief Summary: This is an exploratory study evaluating CS0159 in combination with Semaglutide in metabolic dysfunction-associated fatty liver disease (MAFLD) patients with obesity and type 2 diabetes (T2DM).

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes Obesity Non-alcoholic Fatty Liver Disease

Intervention: DRUG: CS0159

The intervention will include a 12-week treatment period. During the 12-week treatment period, subjects will receive 4mg CS0159 (oral, once daily).

DRUG...